Concourse Financial Group Securities, Inc. Acadia Pharmaceuticals Inc Transaction History

Concourse Financial Group Securities, Inc.

$1.52 Billion
Q1 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 30, 2024	BUY	$17.79 - $30.86 $0 - $0	0 New	0 $0
Q4 2023 Feb 07, 2024	BUY	$20.78 - $31.77 $0 - $0	0 New	0 $0
Q3 2023 Oct 30, 2023	BUY	$20.84 - $33.47 $0 - $0	0 New	0 $0
Q3 2023 Oct 25, 2023	SELL	$20.84 - $33.47 $2,084 - $3,347	-100 Closed	0 $0
Q4 2022 Jan 30, 2023	BUY	$14.2 - $18.63 $1,420 - $1,863	100 New	100 $0

Q3 2022 Nov 15, 2022	SELL	$14.11 - $18.27 $1,411 - $1,827	-100 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$19.4 - $27.42 $1,939 - $2,742	-100 Reduced 50.0%	100 $0
Q1 2021 May 13, 2021	SELL	$25.02 - $54.99 $2,502 - $5,499	-100 Reduced 33.33%	200 $5,000
Q4 2020 Feb 02, 2021	BUY	$41.04 - $56.79 $12,312 - $17,037	300 New	300 $16,000
Q3 2020 Nov 13, 2020	SELL	$36.42 - $57.0 $18,027 - $28,215	-495 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$39.26 - $52.73 $8,637 - $11,600	-220 Reduced 30.77%	495 $24,000
Q1 2020 May 13, 2020	BUY	$31.65 - $46.87 $22,629 - $33,512	715 New	715 $30,000
Q4 2019 Feb 14, 2020	BUY	$36.21 - $51.4 $0 - $0	0 New	0 $0
Q3 2019 Nov 13, 2019	BUY	$22.22 - $44.01 $0 - $0	0 New	0 $0
Q2 2019 Aug 13, 2019	BUY	$23.32 - $28.12 $0 - $0	0 New	0 $0
Q1 2019 May 15, 2019	SELL	$16.17 - $27.38 $2,069 - $3,504	-128 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$14.32 - $22.92 $157 - $252	11 Added 9.4%	128 $2,000
Q3 2018 Nov 13, 2018	BUY	$13.03 - $21.81 $1,524 - $2,551	117 New	117 $2,000

Others Institutions Holding ACAD

# of Institutions

299

Shares Held

158M

Call Options Held

1.88M

Put Options Held

688K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.56B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account